{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T02:19:46Z","timestamp":1785809986473,"version":"3.56.0"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T00:00:00Z","timestamp":1684886400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23 HL166686"],"award-info":[{"award-number":["K23 HL166686"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["23CDA857664"],"award-info":[{"award-number":["23CDA857664"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,14]]},"DOI":"10.1093\/eurheartj\/ehad357","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T22:27:30Z","timestamp":1684967250000},"page":"2908-2910","source":"Crossref","is-referenced-by-count":12,"title":["Neurohormonal blockade in transthyretin amyloidosis: perhaps one size does not fit all?"],"prefix":"10.1093","volume":"44","author":[{"given":"Richard K","family":"Cheng","sequence":"first","affiliation":[{"name":"Division of Cardiology, University of Washington , Seattle, WA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2124-2151","authenticated-orcid":false,"given":"Sarah A M","family":"Cuddy","sequence":"additional","affiliation":[{"name":"Cardiac Amyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02116 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,24]]},"reference":[{"key":"2023081417242425900_ehad357-B1","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1161\/CIRCULATIONAHA.122.060852","article-title":"Impact of earlier diagnosis in cardiac ATTR amyloidosis over the course of 20 years","volume":"146","author":"Ioannou","year":"2022","journal-title":"Circulation"},{"key":"2023081417242425900_ehad357-B2","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1093\/eurheartj\/ehad347","article-title":"Conventional heart failure therapy in cardiac ATTR amyloidosis","volume":"44","author":"Ioannou","year":"2023","journal-title":"Eur Heart J"},{"key":"2023081417242425900_ehad357-B3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCHEARTFAILURE.109.910455","article-title":"Pressure\u2013volume relationships in patients with transthyretin (ATTR) cardiac amyloidosis secondary to V122I mutations and wild-type transthyretin: Transthyretin Cardiac Amyloid Study (TRACS)","volume":"4","author":"Bhuiyan","year":"2011","journal-title":"Circ Heart Fail"},{"key":"2023081417242425900_ehad357-B4","first-page":"e008381","article-title":"Impact of tafamidis and optimal background treatment on physical performance in patients with transthyretin amyloid cardiomyopathy","volume":"15","author":"Eslam","year":"2022","journal-title":"Circ Heart Fail"},{"key":"2023081417242425900_ehad357-B5","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jacc.2022.01.036","article-title":"Critical comparison of documents from scientific societies on cardiac amyloidosis: JACC state-of-the-art review","volume":"79","author":"Rapezzi","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2023081417242425900_ehad357-B6","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/ejhf.2140","article-title":"Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology working group on myocardial and pericardial diseases","volume":"23","author":"Garcia-Pavia","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"2023081417242425900_ehad357-B7","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1161\/CIR.0000000000000792","article-title":"Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American Heart Association","volume":"142","author":"Kittleson","year":"2020","journal-title":"Circulation"},{"key":"2023081417242425900_ehad357-B8","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jacc.2022.11.022","article-title":"2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of Cardiology solution set oversight committee","volume":"81","author":"Kittleson","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"2023081417242425900_ehad357-B9","doi-asserted-by":"crossref","first-page":"e022859","DOI":"10.1161\/JAHA.121.022859","article-title":"Lack of association between neurohormonal blockade and survival in transthyretin cardiac amyloidosis","volume":"10","author":"Cheng","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"2023081417242425900_ehad357-B10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejim.2020.05.015","article-title":"Safety and tolerability of neurohormonal antagonism in cardiac amyloidosis","volume":"80","author":"Aimo","year":"2020","journal-title":"Eur J Intern Med"},{"key":"2023081417242425900_ehad357-B11","doi-asserted-by":"crossref","first-page":"907597","DOI":"10.3389\/fcvm.2022.907597","article-title":"Beta-adrenergic antagonist tolerance in amyloid cardiomyopathy","volume":"9","author":"Ramsell","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023081417242425900_ehad357-B12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jchf.2021.06.007","article-title":"Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT","volume":"9","author":"Sperry","year":"2021","journal-title":"JACC Heart Fail"},{"key":"2023081417242425900_ehad357-B13","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2023081417242425900_ehad357-B14","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1038\/bcj.2017.26","article-title":"Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis","volume":"7","author":"Wechalekar","year":"2017","journal-title":"Blood Cancer J"},{"key":"2023081417242425900_ehad357-B15","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCULATIONAHA.121.055953","article-title":"Doxycycline combined with bortezomib\u2013cyclophosphamide\u2013dexamethasone chemotherapy for newly diagnosed cardiac light-chain amyloidosis: a multicenter randomized controlled trial","volume":"145","author":"Shen","year":"2022","journal-title":"Circulation"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehad357\/50433270\/ehad357.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/31\/2908\/51111006\/ehad357.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/44\/31\/2908\/51111006\/ehad357.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T23:13:53Z","timestamp":1702509233000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/44\/31\/2908\/7177589"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,24]]},"references-count":15,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2023,5,24]]},"published-print":{"date-parts":[[2023,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehad357","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,8,14]]},"published":{"date-parts":[[2023,5,24]]}}}